Immuno-Oncology
Updates in the treatment and management of amyloidosis and the importance of the multidisciplinary team
Amyloidosis is a rare disease in which insoluble amyloid proteins are deposited in tissues or organs, resulting in organ damage….
Date: 11th July 2023
Hemophilia: the current standard of care and the value of novel gene therapies
Over the years, the hemophilia treatment landscape has transformed, with novel agents aiming to improve patient care and quality of…
Date: 5th July 2023
CLL highlights at EHA 2023: latest advances with the use of BTK inhibitors
Bruton’s tyrosine kinase (BTK) inhibitors have transformed the treatment landscape of chronic lymphocytic leukemia (CLL), with both covalent and non-covalent…
Date: 29th June 2023
Myeloma highlights at EHA 2023: CARTITUDE-4 & CARTITUDE-1 updates & the use of MRD in clinical practice
In recent years, CAR-T cell therapy has transformed the myeloma treatment landscape and has provided a valuable option to patients…
Date: 22nd June 2023
Lymphoma highlights at EHA 2023: sequencing bispecifics & CAR-T cells, bridging therapy & toxicity management
The treatment landscape of large B-cell lymphoma (LBCL) has transformed in recent years, with novel immunotherapies including bispecific antibodies and…
Date: 16th June 2023
iwCAR-T Session IV: CAR-T therapy in CLL: challenges, combination approaches and ongoing trials
The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought…
Date: 7th June 2023
MDS 2023 highlights: managing anemia in lower-risk MDS & overcoming treatment failure in higher-risk disease
Therapeutic agents for patients with myelodysplastic syndromes (MDS) are currently under active investigation in clinical trials. The management of cytopenias,…
Date: 31st May 2023
iwCAR-T Session III: CAR-T therapy in AML: ongoing challenges and strategies to improve patient outcomes
The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought…
Date: 24th May 2023
iwCAR-T Session II: CAR-T therapy in ALL: ongoing challenges and future outlooks
The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought…
Date: 18th May 2023
iwCAR-T Session I: CAR-T therapy in lymphoma and the role of bispecific antibodies
The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought…
Date: 11th May 2023
iwMyeloma Session III: reaching a cure for multiple myeloma and concepts that need to be addressed
The 16th International Workshop on Multiple Myeloma (iwMyeloma) 2023 took place in Madrid, Spain, and brought together leading clinicians and…
Date: 2nd May 2023
iwMyeloma Session II: the tumor microenvironment and mechanisms of resistance to targeted therapies
The 16th International Workshop on Multiple Myeloma (iwMyeloma) 2023 took place in Madrid, Spain, and brought together leading clinicians and…
Date: 19th April 2023
